IQVIA Q2 revenue beats estimates; outlook raised
IQV•Drivers of the quarter
- R&D Solutions bookings - Record net new bookings of $3.15 bln in R&D Solutions, up 19% year-over-year, supported revenue growth
- Commercial Solutions growth - Double-digit growth in patient solutions and commercial engagement, and high-single-digit growth in analytics and consulting drove Commercial Solutions revenue
- AI adoption - Increased adoption of AI solutions contributed to organic revenue growth in Commercial Solutions
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $4.37 bln | $4.30 bln (17 Analysts) |
| Q2 Adjusted EPS | Beat | $3.15 | $3.03 (18 Analysts) |
| Q2 EPS | $1.53 |
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell". The average consensus recommendation for the biotechnology & medical research peer group is "buy". Wall Street's median 12-month price target for IQVIA Holdings Inc is $236.50, about 10.9% above its July 27 closing price of $213.22. The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 13 three months ago.
Full-year 2026 outlook raised
- IQVIA raises full-year 2026 revenue guidance to $17.275 bln-$17.475 bln
- Company lifts 2026 adjusted EBITDA forecast to $4.0 bln-$4.05 bln
- IQVIA expects 2026 adjusted diluted EPS of $12.80-$13.00
